To estimate the **Potential Peak Sales** for capmatinib (TABRECTA) in the indication of metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation in the US, EU5 (France, Germany, Italy, Spain, UK), China, and Japan, as well as the **$ value of a 1% share of treated patients** in these geographies, we need to follow a structured approach. Since specific data such as exact patient numbers, pricing, or market penetration may not be publicly available, I will outline the methodology and provide a reasonable estimate based on general market data, epidemiology, and assumptions. If you have specific data (e.g., pricing or patient numbers), I can refine the calculations.

---

## Step 1: Define Key Parameters and Assumptions

1. **Indication and Target Population**:

- Capmatinib is approved for metastatic NSCLC patients with MET exon 14 skipping mutation.

- MET exon 14 skipping mutations occur in approximately **3-4% of NSCLC patients**.

- NSCLC accounts for about **85% of all lung cancer cases**.

2. **Epidemiology of NSCLC**:

- Annual incidence of lung cancer (all types) in the geographies (2020 estimates from sources like GLOBOCAN):

- US: ~228,000 new cases

- EU5: ~320,000 new cases (combined)

- China: ~820,000 new cases

- Japan: ~130,000 new cases

- NSCLC proportion (85%):

- US: ~194,000 cases

- EU5: ~272,000 cases

- China: ~697,000 cases

- Japan: ~110,500 cases

- MET exon 14 skipping mutation (3.5% average of NSCLC cases):

- US: ~6,800 patients

- EU5: ~9,500 patients

- China: ~24,400 patients

- Japan: ~3,900 patients

- Total eligible patients across geographies: ~44,600 patients annually.

3. **Treatment Rate**:

- Not all eligible patients will be treated due to factors like diagnosis rates, access to testing, and healthcare system differences.

- Assume **50-70% of eligible patients** are diagnosed and treated in developed markets (US, EU5, Japan) and **30-50% in China** due to differences in healthcare access.

4. **Market Share**:

- Assuming capmatinib captures **20-30% of treated patients** in this indication, as per the query.

5. **Drug Pricing**:

- Capmatinib's annual cost in the US is approximately **$200,000 per patient** (based on typical pricing for targeted oncology therapies; adjust if specific data is available).

- Pricing in other regions is typically lower:

- EU5: ~60-70% of US price (~$120,000-$140,000)

- Japan: ~70-80% of US price (~$140,000-$160,000)

- China: ~30-40% of US price (~$60,000-$80,000)

6. **Peak Sales Timeline**:

- Peak sales are typically reached 5-7 years post-launch, assuming no major competition or patent expiry.

---

## Step 2: Estimate Treated Patients and Market Share

- **Treated Patients** (using midpoint of treatment rate assumptions):

- US: 6,800 * 60% = ~4,100 patients

- EU5: 9,500 * 60% = ~5,700 patients

- China: 24,400 * 40% = ~9,800 patients

- Japan: 3,900 * 60% = ~2,300 patients

- Total treated patients: ~22,000

- **Capmatinib's Treated Patients (20-30% share)**:

- Using midpoint of 25% share:

- US: 4,100 * 25% = ~1,025 patients

- EU5: 5,700 * 25% = ~1,425 patients

- China: 9,800 * 25% = ~2,450 patients

- Japan: 2,300 * 25% = ~575 patients

- Total capmatinib-treated patients: ~5,475

---

## Step 3: Calculate Potential Peak Sales

- **Annual Revenue per Region** (using midpoint pricing):

- US: 1,025 patients * $200,000 = **$205 million**

- EU5: 1,425 patients * $130,000 = **$185 million**

- China: 2,450 patients * $70,000 = **$171 million**

- Japan: 575 patients * $150,000 = **$86 million**

- **Total Peak Sales**: $205M + $185M + $171M + $86M = **~$647 million**

- **Range of Peak Sales (20-30% share)**:

- At 20% share: ~$518 million

- At 30% share: ~$776 million

- **Midpoint Estimate: ~$647 million**

---

## Step 4: Calculate $ Value of 1% Share of Treated Patients

- **1% Share of Treated Patients**:

- US: 4,100 * 1% = 41 patients * $200,000 = **$8.2 million**

- EU5: 5,700 * 1% = 57 patients * $130,000 = **$7.4 million**

- China: 9,800 * 1% = 98 patients * $70,000 = **$6.9 million**

- Japan: 2,300 * 1% = 23 patients * $150,000 = **$3.5 million**

- **Total $ Value of 1% Share**: $8.2M + $7.4M + $6.9M + $3.5M = **~$26 million**

---

## Final Answer

1. **Potential Peak Sales for Capmatinib** in the US, EU5, China, and Japan for metastatic NSCLC with MET exon 14 skipping mutation (assuming 20-30% share of treated patients):

- Range: **$518 million to $776 million**

- Midpoint Estimate: **~$647 million**

2. **$ Value of 1% Share of Treated Patients** in these geographies:

- US: **$8.2 million**

- EU5: **$7.4 million**

- China: **$6.9 million**

- Japan: **$3.5 million**

- Total: **~$26 million**

---

## Notes and Caveats

- These estimates are based on assumptions about epidemiology, treatment rates, pricing, and market share. Real-world data may vary due to competition (e.g., other MET inhibitors like tepotinib), changes in pricing, or access to diagnostics.

- If specific data on capmatinib's pricing, patient numbers, or market dynamics is available, the calculations can be refined.

- Peak sales may be influenced by future approvals in additional indications or geographies, patent life, and generic entry.